`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`ARKEMA AND ARKEMA FRANCE
`Petitioner,
`v.
`
`HONEYWELL INTERNATIONAL INC.,
`Patent Owner.
`
`
`
`Case No.: PGR2016-00011
`Patent No.: 9,157,017
`
`
`PATENT OWNER’S REPLY IN SUPPORT OF ITS
`
`MOTION TO EXCLUDE PURSUANT TO 37 C.F.R. § 42.64(C)
`
`
`
`
`
`
`
`
`
`
`
`
`
`Honeywell submits this reply in support of its motion to exclude Petitioner’s
`
`Exhibit 1163 as hearsay.
`
`I.
`
`INTRODUCTION
`
`Recognizing the hearsay nature of Exhibit 1163, Arkema tries to salvage its
`
`exhibit by claiming that it is “used for the non-hearsay purpose of impeaching Dr.
`
`Bivens.” Opp. at 3. But Exhibit 1163 cannot be used for impeachment evidence
`
`because it is not a prior statement by Dr. Bivens, but instead, an earlier declaration
`
`of someone unrelated in any way to Dr. Bivens. As explained in Honeywell’s
`
`motion to exclude, Arkema is transparently attempting to use Exhibit 1163 as
`
`substantive rebuttal evidence and offering it for its truth, despite its plainly hearsay
`
`nature. Further supporting Honeywell’s motion, Arkema admits that Exhibit 1163
`
`is not something it is even relying on as necessary to support its contentions
`
`regarding the alleged desirability of a low-GWP refrigerant during the time period
`
`leading up to Honeywell’s invention. Accordingly, because Exhibit 1163 is
`
`undisputedly hearsay, is being offered for its truth, and is admittedly of little to no
`
`relevance to Arkema’s contentions, it should be excluded.
`
`II. ARGUMENT
`
`A. Exhibit 1163 Is Hearsay
`
`Arkema attempts to avoid the clear case for exclusion by arguing that it is
`
`not relying on Exhibit 1163 for its truth, but rather for “impeaching Dr. Bivens.”
`
`Opp. at 1, 4. Arkema does not cite any support for its proposition that using a
`
`
`
`
`1
`
`
`
`
`
`document that the witness did not write, had never seen, and disagrees with is
`
`proper “impeachment.” See Ex. 1177 at 30:4-18; 32:18-21. And for good reason:
`
`because that is neither proper impeachment nor an end-run around Honeywell’s
`
`valid hearsay objection. See Fisher v. United States, 78 Fed. Cl. 710, 712–13
`
`(2007) (improper to impeach expert with statements “not made by the witness
`
`himself”). Under Arkema’s theory, every piece of evidence could conceivably
`
`come in as “impeachment” evidence if it in any way is offered by a party in
`
`response to an opposing expert’s opinion. The rules of evidence, and basic fairness,
`
`say otherwise.
`
`Traditionally, impeachment “involves evidence that calls into question the
`
`witness's veracity. It deals with ‘matters like the bias or interest of a witness, his or
`
`her capacity to observe an event in issue, or a prior statement of the witness
`
`inconsistent with his or her current testimony.’” United States v. Harris, 557 F.3d
`
`938, 942 (8th Cir. 2009) (citation omitted). Arkema does not use Exhibit 1163 for
`
`any of those impeachment purposes, or for any impeachment purpose in the
`
`Federal Rules. See Fed. R. Evid. 801(d)(1) (advisory committee notes) (“Prior
`
`inconsistent statements traditionally have been admissible to impeach….”); Fed. R.
`
`Evid. 609 (governing impeachment by evidence of a criminal conviction); Fed. R.
`
`Evid. 613 (governing use of prior inconsistent statements by a witness); Fed. R.
`
`Evid. 607 (equating impeachment with “attack[ing] the witness’s credibility”).
`
`
`
`
`2
`
`
`
`
`
`Arkema instead attempts to use Exhibit 1163 to substantively rebut, rather
`
`than impeach, Dr. Bivens’ assertion that “[t]he only logical conclusion from this is
`
`that Inagaki, like all others skilled in the art at that time, presumed that all of the
`
`compounds covered by its formula would share the same toxicity and other
`
`concerns.” Opp. at 3 (citing Ex. 2126 ¶ 91) (emphasis Arkema’s). Arkema points
`
`to two things as “impeaching” Dr. Bivens’ above assertion: (1) his “failure to
`
`consider Dr. Shibanuma’s declaration”; and (2) his “admission that he, in fact, did
`
`not know why Daikin did not pursue Inagaki.” Opp. at 4.
`
`Dr. Shibanuma’s declaration in no way supports those points. Dr.
`
`Shibanuma’s declaration says nothing about Dr. Bivens’ consideration of it in this
`
`proceeding. How could it? The declaration was authored in 2014, and this
`
`proceeding began in 2016.
`
`Nor does Dr. Shibanuma’s declaration say anything about Dr. Bivens’
`
`knowledge about why Daikin did not pursue Inagaki. Why would it? What reason
`
`would Dr. Shibanuma have to talk about Dr. Bivens’ knowledge in his declaration?
`
`Indeed it does no such thing.
`
`Rather, Arkema cites only portions of Dr. Bivens’ deposition transcript to
`
`support its two above points. Opp. at 4 (citing Ex. 1177). By Arkema’s own
`
`admission then, Exhibit 1163 is not even impeachment evidence.
`
`
`
`
`3
`
`
`
`
`
`To the contrary, Arkema has plainly been called out for trying to use Exhibit
`
`1163—a declaration from a different proceeding by someone Arkema did not offer
`
`as a declarant here—to prove the truth of the matter asserted therein. By submitting
`
`it as an exhibit, Arkema intends the Board to weigh Exhibit 1163 against Dr.
`
`Bivens’ conclusions. Opp. at 4 (asserting Ex. 1163 is relevant to showing the
`
`“baseless[ness]” of Dr. Bivens’ assertion). Yet implicit in that weighing is the
`
`assumption that the Board will consider the statements in Exhibit 1163 for their
`
`truth. If not offered for their truth, statements by someone other than Dr. Bivens
`
`cannot possibly “impeach” Dr. Bivens’ conclusions. The whole purpose of
`
`Arkema’s reliance on Exhibit 1163 is to allegedly provide evidence to the Board as
`
`to why Daikin abandoned the Inagaki reference—i.e. for the truth of Arkema’s
`
`assertion.
`
`B. Honeywell’s Motion Did Not Include Improper Substantive
`Arguments
`
`Arkema also argues that Honeywell’s motion includes improper substantive
`
`arguments. To the contrary, Honeywell properly set forth evidentiary bases for
`
`excluding Exhibit 1163, namely: (1) it does not support Arkema’s propositions,
`
`and should therefore be excluded on that basis as irrelevant, and (2) does not carry
`
`any guarantees of trustworthiness to somehow qualify under the residual hearsay
`
`exception despite its facially hearsay nature. See Motion at 5, 7.
`
`
`
`
`4
`
`
`
`
`
`III. CONCLUSION
`
`For the foregoing reasons, Patent Owner moves that Exhibit 1163 be
`
`excluded from the record.
`
`Respectfully submitted,
`
`/s/ Gregg F. LoCascio, P.C.
`
`Gregg F. LoCascio, P.C. (Reg. No. 55,396)
`Noah Frank (Reg. No. 67,279)
`glocascio@kirkland.com
`noah.frank@kirkland.com
`KIRKLAND & ELLIS LLP
`655 Fifteenth Street, NW
`Suite 1200
`Washington, DC 20005
`Telephone: (202) 879-5200
`Fax: (202) 879-5200
`
`Attorneys For Patent Owner
`
`
`
`
`Date: April 24, 2017
`
`Eugene Goryunov (Reg. No. 61,579)
`egoryunov@kirkland.com
`KIRKLAND & ELLIS LLP
`300 North LaSalle
`Chicago, Illinois 60654
`Telephone: (312) 862-2000
`Fax: (312) 862-2200
`
`
`
`
`
`
`
`
`
`
`5
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Patent
`
`Owner’s Reply in Support of its Motion to Exclude was served on the 24th day of
`
`April, 2017, via electronic mail directed to counsel of record for the Petitioners:
`
`Mark D. Sweet
`Mark J. Feldstein
`Erin M. Sommers
`Charles W. Mitchell
`
`
`mark.sweet@finnegan.com
`mark.feldstein@finnegan.com
`erin.sommers@finnegan.com
`charles.mitchell@finnegan.com
`Arkema_PTAB@finnegan.com
`
`
`
`
`
`
`
`
`/s/ Gregg F. LoCascio, P.C.
`Gregg F. LoCascio, P.C.
`
`
`
`
`
`6
`
`